Compare ALAR & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALAR | XCUR |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5M | 13.7M |
| IPO Year | 2018 | 2017 |
| Metric | ALAR | XCUR |
|---|---|---|
| Price | $1.87 | $1.34 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $14.00 | N/A |
| AVG Volume (30 Days) | 146.7K | ★ 242.7K |
| Earning Date | 05-28-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 83.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $24.51 | N/A |
| Revenue Next Year | $33.43 | N/A |
| P/E Ratio | $44.31 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.62 | $1.27 |
| 52 Week High | $18.00 | $9.48 |
| Indicator | ALAR | XCUR |
|---|---|---|
| Relative Strength Index (RSI) | 25.52 | 27.41 |
| Support Level | $1.62 | N/A |
| Resistance Level | $7.54 | $2.02 |
| Average True Range (ATR) | 0.13 | 0.16 |
| MACD | 0.24 | -0.01 |
| Stochastic Oscillator | 53.06 | 4.62 |
Alarum Technologies Ltd is a software-as-a-service (SaaS) provider operating mainly in the web data collection market, offering web data collection and a private internet browsing platform. The company's Web Data Collection products offer secure, fast, and anonymous IP Proxy Network Solutions & Services, or IPPN or IPPN Solutions, to its business customers which, in turn, enables them to anonymously and securely browse the internet as well as to collect data from any publicly available source on the web, for their business purpose. The company operates in one segment: web data collection. Geographically, it derives maximum revenue from China, followed by the United States, Europe, Hong Kong, Asia-Pacific, U.K. Virgin Islands, Israel, United Arab Emirates, Middle East & Africa and other.
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.